Non-Small Cell Lung Cancer

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

By

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

By

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

By

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

By

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

By

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

Vandetanib Potentially Efficacious in RET-Rearranged NSCLC

By

In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC

By

This study focused on determining the effectiveness of a short-term high-intensity interval training (HIIT) program to improve patients' cardiorespiratory fitness prior to NSCLC resection.

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

Atezolizumab Granted FDA Approval for Specific Cases of NSCLC

By

Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

First-line Pembrolizumab + Chemo Could Be Effective for Non-squamous NSCLC

By

The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.

Lenvatinib Shows Promising Activity in RET+ NSCLC

Lenvatinib Shows Promising Activity in RET+ NSCLC

By

Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.

Study Supports Routine Use of IMRT for Locally Advanced NSCLC

Study Supports Routine Use of IMRT for Locally Advanced NSCLC

By

IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.

SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC

By

Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.

WBRT Adds Little Benefit for NSCLC With Brain Metastases

WBRT Adds Little Benefit for NSCLC With Brain Metastases

By

Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.

TKIs Improve Overall Survival in NSCLC Patients With Leptomeningeal Metastases

TKIs Improve Overall Survival in NSCLC Patients With Leptomeningeal Metastases

By

Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.

Study Evaluates Incidence of PD-1 Blockade-related Pneumonitis

By

Pneumonitis related to the use of PD-1 inhibitor therapy is higher among patients with NSCLC and RCC, and during combination therapy.

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

By

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Study Better Characterizes Immunotherapy-related Skin Toxicities

By

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

By

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

By

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

By

In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.

Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung Cancer

By

Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

By

The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

By

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

By

The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

By

When more quality measures are incorporated into patient care, survival rates for patients with stage IIIA non-small cell lung cancer (NSCLC) increase, but only 13% of eligible patients actually receive all 4 recommended quality measures.

Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung Cancer

By

High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

[Cancer Management and Research] This research examines the use of proactive GI AE management strategies for patients with non-small-cell lung cancer being treated with ceritinib.

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

Necitumumab With Chemotherapy Beneficial for Patients With EGFR-expressing NSCLC

By

The most benefit from adding necitumumab to chemotherapy with gemcitabine and cisplatin occurred for patients whose advanced squamous NSCLC expressed EGFR.

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC

By

Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.

Osimertinib Proven Effective as First-line Therapy for EGFR-positive NSCLC

By

Osimertinib effectively treats EGFR-mutated non-small cell lung cancer that has the T790M mutation, according to recent study findings.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs